Literature DB >> 19654288

Unwelcome complement.

Maciej M Markiewski1, John D Lambris.   

Abstract

For decades, the complement system has been recognized as an effector arm of the innate immunity system that contributes to the destruction of tumor cells. However, recent studies have challenged this paradigm by demonstrating that a complement component, the anaphylatoxin C5a, promotes the growth of malignant tumors in a mouse model of cervical carcinoma. The effect of C5a on tumor growth was associated with the recruitment of myeloid-derived suppressor cells to tumors, followed by the activation of these cells. These unexpected findings identify the complement system as a potential new target for anticancer immunotherapy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19654288      PMCID: PMC2727567          DOI: 10.1158/0008-5472.CAN-09-1918

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  20 in total

1.  Complement resistance of human carcinoma cells depends on membrane regulatory proteins, protein kinases and sialic acid.

Authors:  N Donin; K Jurianz; L Ziporen; S Schultz; M Kirschfink; Z Fishelson
Journal:  Clin Exp Immunol       Date:  2003-02       Impact factor: 4.330

Review 2.  Points of control in inflammation.

Authors:  Carl Nathan
Journal:  Nature       Date:  2002 Dec 19-26       Impact factor: 49.962

Review 3.  Drug evaluation: the C5a receptor antagonist PMX-53.

Authors:  Jörg Köhl
Journal:  Curr Opin Mol Ther       Date:  2006-12

Review 4.  Inflammation and cancer: back to Virchow?

Authors:  F Balkwill; A Mantovani
Journal:  Lancet       Date:  2001-02-17       Impact factor: 79.321

5.  Expression of complement factor H by lung cancer cells: effects on the activation of the alternative pathway of complement.

Authors:  Daniel Ajona; Zafira Castaño; Mercedes Garayoa; Enrique Zudaire; Maria J Pajares; Alfredo Martinez; Frank Cuttitta; Luis M Montuenga; Ruben Pio
Journal:  Cancer Res       Date:  2004-09-01       Impact factor: 12.701

6.  Persistent complement activation on tumor cells in breast cancer.

Authors:  F Niculescu; H G Rus; M Retegan; R Vlaicu
Journal:  Am J Pathol       Date:  1992-05       Impact factor: 4.307

Review 7.  Inflammation and cancer.

Authors:  Lisa M Coussens; Zena Werb
Journal:  Nature       Date:  2002 Dec 19-26       Impact factor: 49.962

8.  Increased activity of the mannan-binding lectin complement activation pathway in patients with colorectal cancer.

Authors:  H Ytting; J C Jensenius; I J Christensen; S Thiel; H J Nielsen
Journal:  Scand J Gastroenterol       Date:  2004-07       Impact factor: 2.423

9.  Activity and activation of the complement system in patients being operated on for cancer of the colon.

Authors:  G Baatrup; N Qvist; A Junker; K E Larsen; C Zimmermann-Nielsen
Journal:  Eur J Surg       Date:  1994-09

10.  Ascitic complement system in ovarian cancer.

Authors:  L Bjørge; J Hakulinen; O K Vintermyr; H Jarva; T S Jensen; O E Iversen; S Meri
Journal:  Br J Cancer       Date:  2005-03-14       Impact factor: 7.640

View more
  29 in total

1.  Induction of complement C3a receptor responses by kallikrein-related peptidase 14.

Authors:  Katerina Oikonomopoulou; Robert A DeAngelis; Hui Chen; Eleftherios P Diamandis; Morley D Hollenberg; Daniel Ricklin; John D Lambris
Journal:  J Immunol       Date:  2013-09-06       Impact factor: 5.422

2.  MODELING DEPENDENT GENE EXPRESSION.

Authors:  Donatello Telesca; Peter Müller; Giovanni Parmigiani; Ralph S Freedman
Journal:  Ann Stat       Date:  2012-06-11       Impact factor: 4.028

3.  Blocking C5aR signaling promotes the anti-tumor efficacy of PD-1/PD-L1 blockade.

Authors:  Haoran Zha; Xiao Han; Ying Zhu; Fei Yang; Yongsheng Li; Qijing Li; Bo Guo; Bo Zhu
Journal:  Oncoimmunology       Date:  2017-07-13       Impact factor: 8.110

4.  The Ribosomal Protein S19 Suppresses Antitumor Immune Responses via the Complement C5a Receptor 1.

Authors:  Maciej M Markiewski; Surya Kumari Vadrevu; Sharad K Sharma; Navin Kumar Chintala; Shanawaz Ghouse; Jun-Hung Cho; David P Fairlie; Yvonne Paterson; Aristotelis Astrinidis; Magdalena Karbowniczek
Journal:  J Immunol       Date:  2017-02-22       Impact factor: 5.422

5.  An antimicrobial peptide regulates tumor-associated macrophage trafficking via the chemokine receptor CCR2, a model for tumorigenesis.

Authors:  Ge Jin; Hameem I Kawsar; Stanley A Hirsch; Chun Zeng; Xun Jia; Zhimin Feng; Santosh K Ghosh; Qing Yin Zheng; Aimin Zhou; Thomas M McIntyre; Aaron Weinberg
Journal:  PLoS One       Date:  2010-06-08       Impact factor: 3.240

6.  CXCR7 protein expression correlates with elevated mmp-3 secretion in breast cancer cells.

Authors:  Brian A Zabel; Zhenhua Miao; Nu L Lai; Yu Wang; Susanna Lewén; Robert D Berahovich; Juan C Jaén; Thomas J Schall
Journal:  Oncol Lett       Date:  2010-09-01       Impact factor: 2.967

7.  Serum peptidomic biomarkers for pulmonary metastatic melanoma identified by means of a nanopore-based assay.

Authors:  Jia Fan; Yi Huang; Inez Finoulst; Hung-Jen Wu; Zaian Deng; Rong Xu; Xiaojun Xia; Mauro Ferrari; Haifa Shen; Ye Hu
Journal:  Cancer Lett       Date:  2012-11-27       Impact factor: 8.679

8.  Opposing roles for complement component C5a in tumor progression and the tumor microenvironment.

Authors:  Lacey Gunn; Chuanlin Ding; Min Liu; Yunfeng Ma; Chunjian Qi; Yihua Cai; Xiaoling Hu; Deep Aggarwal; Huang-Ge Zhang; Jun Yan
Journal:  J Immunol       Date:  2012-08-22       Impact factor: 5.422

9.  Complement as Prognostic Biomarker and Potential Therapeutic Target in Renal Cell Carcinoma.

Authors:  Britney Reese; Ashok Silwal; Elizabeth Daugherity; Michael Daugherity; Mahshid Arabi; Pierce Daly; Yvonne Paterson; Layton Woolford; Alana Christie; Roy Elias; James Brugarolas; Tao Wang; Magdalena Karbowniczek; Maciej M Markiewski
Journal:  J Immunol       Date:  2020-11-06       Impact factor: 5.422

10.  Complement Membrane Attack and Tumorigenesis: A SYSTEMS BIOLOGY APPROACH.

Authors:  Laurence D Towner; Richard A Wheat; Timothy R Hughes; B Paul Morgan
Journal:  J Biol Chem       Date:  2016-05-19       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.